TREOS Bio Presents New PEPI Technology Data at EACR 2026, Including Six-Year Cancer-Free Outcome in MSS Metastatic Colorectal Cancer (mCRC)

Three presentations highlight off-the-shelf immunotherapy in Microsatellite Stable (MSS) mCRC, biopsy-free target selection and broader platform potential across difficult-to-treat cancers Three presentations highlight off-the-shelf immunotherapy in Microsatellite Stable (MSS) mCRC, biopsy-free target selection and broader platform potential across difficult-to-treat cancers